International controlled study of revascularization and outcomes following COVID‐positive mechanical thrombectomy

Previous studies suggest that mechanisms and outcomes in patients with COVID‐19‐associated stroke differ from those in patients with non‐COVID‐19‐associated strokes, but there is limited comparative evidence focusing on these populations. The aim of this study, therefore, was to determine if a significant association exists between COVID‐19 status with revascularization and functional outcomes following thrombectomy for large vessel occlusion (LVO), after adjustment for potential confounding factors.

[1]  D. Liebeskind,et al.  Abstract TP93: Interaction Of Ethnicity And Arrival Method On Thrombectomy Delay: The Society Of Vascular And Interventional Neurology Multicenter Collaboration , 2022, Stroke.

[2]  A. Venkatesan,et al.  Acute Viral Illnesses and Ischemic Stroke , 2021, Stroke.

[3]  C. Nolte,et al.  Maintenance of Acute Stroke Care Service During the COVID-19 Pandemic Lockdown , 2021, Stroke.

[4]  S. Mayer,et al.  Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic , 2021, Stroke and vascular neurology.

[5]  Thalia Shoshana Field,et al.  Global Impact of COVID-19 on Stroke Care and IV Thrombolysis , 2021, Neurology.

[6]  D. Yavagal,et al.  Incidence, Characteristics and Outcomes of Large Vessel Stroke in COVID-19 Cohort: An International Multicenter Study , 2021, Neurosurgery.

[7]  anonymous,et al.  Correction to: Influence of the COVID-19 Pandemic on Treatment Times for Acute Ischemic Stroke: The Society of Vascular and Interventional Neurology Multicenter Collaboration. , 2021, Stroke.

[8]  D. Liebeskind,et al.  Endovascular thrombectomy time metrics in the era of COVID-19: observations from the Society of Vascular and Interventional Neurology Multicenter Collaboration , 2021, Journal of NeuroInterventional Surgery.

[9]  Á. Chamorro,et al.  Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry , 2021, BMC Neurology.

[10]  Seung-sik Hwang,et al.  Disease severity classification and COVID-19 outcomes, Republic of Korea. , 2020, Bulletin of the World Health Organization.

[11]  A. Mebazaa,et al.  Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients , 2021, Frontiers in Physiology.

[12]  D. Guidetti,et al.  Letter by Morelli et al Regarding Article, "Acute Stroke Care Is at Risk in the Era of COVID-19: Experience at a Comprehensive Stroke Center in Barcelona". , 2020, Stroke.

[13]  M. Banach,et al.  Pathophysiology of Cardiovascular Complications in COVID-19 , 2020, Frontiers in Physiology.

[14]  M. Elkind,et al.  Infection as a Stroke Risk Factor and Determinant of Outcome After Stroke. , 2020, Stroke.

[15]  Á. Chamorro,et al.  Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry , 2020, International journal of stroke : official journal of the International Stroke Society.

[16]  H. Tabassum,et al.  Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic , 2020, Molecular Neurobiology.

[17]  J. Mocco,et al.  Association of Coronavirus Disease (COVID-19) With Large Vessel Occlusion Strokes: A Case-Control Study. , 2020, AJR. American journal of roentgenology.

[18]  G. Tosato,et al.  Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection , 2020, Cells.

[19]  M. Cosottini,et al.  European Multicenter Study of ET-COVID-19 , 2020, Stroke.

[20]  Simon Li,et al.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.

[21]  A. Mishra,et al.  Mechanisms of stroke and the role of anticoagulants in COVID-19 , 2020, Journal of the Formosan Medical Association.

[22]  N. Herial,et al.  Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019 , 2020, International Journal of Stroke.

[23]  A. Spiotta,et al.  Letter: May Cooler Heads Prevail During a Pandemic: Stroke in COVID-19 Patients or COVID-19 in Stroke Patients? , 2020, Neurosurgery.

[24]  É. Azoulay,et al.  The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection , 2020, Critical Care.

[25]  N. Herial,et al.  Letter: Thrombotic Neurovascular Disease in COVID-19 Patients , 2020, Neurosurgery.

[26]  Daishi Tian,et al.  Clinical Characteristics and Outcomes of COVID-19 Patients With a History of Stroke in Wuhan, China , 2020, Stroke.

[27]  P. Meyers,et al.  Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics , 2020, Journal of NeuroInterventional Surgery.

[28]  N. Henninger,et al.  SARS2-CoV-2 and Stroke in a New York Healthcare System , 2020, Stroke.

[29]  Simon A. Jones,et al.  COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome , 2020, Journal of the Neurological Sciences.

[30]  S. Mayer,et al.  Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights , 2020, Journal of Stroke and Cerebrovascular Diseases.

[31]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[32]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[33]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[34]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[35]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[36]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[37]  R. Kahwash,et al.  Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? , 2020, Circulation.

[38]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[39]  R. McIntyre,et al.  Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series , 2020, Journal of Thrombosis and Haemostasis.

[40]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[41]  R. Liu,et al.  Prominent changes in blood coagulation of patients with SARS-CoV-2 infection , 2020, Clinical chemistry and laboratory medicine.

[42]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[43]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[44]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[45]  W. Feng,et al.  Factors affecting post-stroke motor recovery: Implications on neurotherapy after brain injury , 2018, Behavioural Brain Research.

[46]  H. Whitaker,et al.  Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland , 2018, European Respiratory Journal.

[47]  Toshio Tanaka,et al.  IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.

[48]  Shuzhen Chen,et al.  Neuronal over-expression of ACE2 protects brain from ischemia-induced damage , 2014, Neuropharmacology.

[49]  C. Zhang,et al.  Angiotensin-Converting Enzyme 2 Priming Enhances the Function of Endothelial Progenitor Cells and Their Therapeutic Efficacy , 2013, Hypertension.

[50]  M. Raizada,et al.  Cerebroprotection by angiotensin‐(1–7) in endothelin‐1‐induced ischaemic stroke , 2011, Experimental physiology.

[51]  Gary King,et al.  MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .

[52]  S. Sriramula,et al.  ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[53]  P. Giraudon,et al.  Inflammation in neuroviral diseases , 2010, Journal of Neural Transmission.

[54]  F. Dominici,et al.  Angiotensin‐(1–7) through AT2 receptors mediates tyrosine hydroxylase degradation via the ubiquitin–proteasome pathway , 2009, Journal of neurochemistry.

[55]  J. Arenillas,et al.  Acute Hyperglycemia State Is Associated With Lower tPA-Induced Recanalization Rates in Stroke Patients , 2005, Stroke.

[56]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[57]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[58]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[59]  A. Lo,et al.  Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS‐CoV) and its putative receptor, angiotensin‐converting enzyme 2 (ACE2) , 2004, The Journal of pathology.

[60]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[61]  Nigel M Hooper,et al.  ACE2: from vasopeptidase to SARS virus receptor , 2004, Trends in Pharmacological Sciences.

[62]  R. Santos,et al.  Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. , 2003, American journal of physiology. Heart and circulatory physiology.

[63]  G. Pellegrini,et al.  Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat , 2001, Acta Diabetologica.

[64]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[65]  D. Diz,et al.  Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. , 1989, The American journal of physiology.